27 Matching Annotations
  1. May 2026
    1. Total AI computing capacity has been doubling approximately every seven months

      AI计算能力每7个月翻倍的增长率远超摩尔定律(约18-24个月翻倍),反映了AI领域对计算资源的极度渴求和产业投入的快速增长。这种指数级增长趋势是不可持续的,将面临物理极限、能源供应和制造成本等多重挑战,可能在未来几年内放缓。

  2. Apr 2026
    1. In early April, we shared that more than 3 million developers were using Codex every week. Just two weeks later, that number has grown to more than 4 million.

      这表明Codex的开发者采用率在两周内增长了33.3%(从300万增加到400万),这是一个惊人的增长率。这种快速增长反映了开发者对AI编程工具的强烈需求,也暗示了Codex可能正在经历病毒式传播或企业快速采用阶段。

    1. Reasoning models show both a one-off jump in performance and a roughly 2-3x faster trend compared to non-reasoning models.

      推理模型性能提升速度是非推理模型的2-3倍,这是一个显著的增长率差异。这个倍数关系表明推理模型确实带来了质的飞跃,但需要考虑这是否反映了模型架构的根本改进,还是仅仅由于更多计算资源的投入。

    2. Reasoning models show both a one-off jump in performance and a roughly 2-3x faster trend compared to non-reasoning models.

      推理模型比非推理模型显示出2-3倍的性能提升速度,这是一个显著的增长率差异。这个倍数差异表明推理模型的引入可能代表了AI发展的一个重要转折点。然而,文章也指出无法确定精确的增长率,因为多种非线性拟合都能很好地解释数据。

  3. Mar 2026
    1. Selection

      Initial Assessment: Transthoracic echocardiography (TTE) is recommended at diagnosis to assess aortic valve anatomy, valve function, and thoracic aortic diameters. CT or MRI is reasonable for comprehensive anatomic assessment. [1]

      Surveillance Imaging: The choice depends on aneurysm location: [2]

      Aortic root/proximal ascending aorta: TTE can be used if measurements correlate well with CT/MRI

      Mid-ascending, arch, or descending thoracic aorta: CT or MRI is recommended

      MRI is preferred for long-term surveillance to avoid cumulative radiation exposure from serial CT scans [1][3]

      Surveillance Intervals

      Size-Based Recommendations: [2-4]

      <4.0 cm: Every 2-3 years if stable

      4.0-4.4 cm: Every 2 years

      4.5-4.9 cm: Annually

      5.0-5.4 cm: Every 6-12 months (consider optimization for repair)

      ≥5.5 cm: Surgical evaluation indicated

      Initial surveillance: Obtain follow-up imaging at 6-12 months after diagnosis to establish the growth rate. If stable, adjust interval based on size. [1]

      Growth rate considerations: Descending thoracic aneurysms grow faster than ascending aneurysms (mean 2.76 mm/year vs 1 mm/year overall). Growth accelerates exponentially above 4.5 cm diameter. [3-4]

    2. Earlier intervention is reasonable when high-risk features are present, including rapid growth (≥0.5 cm/year), symptomatic aneurysm, saccular morphology, or penetrating atherosclerotic ulcers

  4. Feb 2025
  5. Aug 2022
  6. Mar 2022
  7. Feb 2022
    1. Cornelius Roemer. (2022, February 12). Fantastic work by @UKHSA comparing serial intervals of BA.1, BA.2 and Delta as published in the most recent technical briefing. BA.2 seems to have even shorter serial interval than BA.1 This could help explain different relative growth rates of BA.2 vs BA.1 in different countries https://t.co/Gch94Ew8CX [Tweet]. @CorneliusRoemer. https://twitter.com/CorneliusRoemer/status/1492434232664375304

    1. Trevor Bedford. (2022, January 28). Omicron viruses can be divided into two major groups, referred to as PANGO lineages BA.1 and BA.2 or @nextstrain clades 21K and 21L. The vast majority of globally sequenced Omicron have been 21K (~630k) compared a small minority of 21L (~18k), but 21L is gaining ground. 1/15 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1487105396879679488

  8. Dec 2021
  9. Nov 2021
  10. Jun 2021
    1. Bolze, A., Cirulli, E. T., Luo, S., White, S., Cassens, T., Jacobs, S., Nguyen, J., Ramirez, J. M., Sandoval, E., Wang, X., Wong, D., Becker, D., Laurent, M., Lu, J. T., Isaksson, M., Washington, N. L., & Lee, W. (2021). Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States [Preprint]. Infectious Diseases (except HIV/AIDS). https://doi.org/10.1101/2021.06.20.21259195

  11. May 2021
  12. Mar 2021
  13. Nov 2020
  14. Jul 2020
  15. May 2020
  16. Sep 2016
    1. The group has reported sustained revenue and operating income growth over the review period, with revenue rising by a five-year CAGR of 14% to reach KES51.6bn in F15 and operating income rising by a CAGR of 26% to KES2.2bn. However, profits have been heavily eroded by rising interest charges, associated with the large quantum of debt that has been used to fund growth. Thus, operating profit of KES2.2bn in F14 and F15 equated to net interest cover of 1.2x in both years, compared to 1.8x in F13. Moreover, NPBT has decreased from KES823m in F13 to KES305m in F15.

      Nakumatt profitability point